Pfizer Gets European Commission Approval for Zirabev, an Industrial Info Market Brief
Pfizer Gets European Commission Approval for Zirabev, an Industrial Info Market Brief
Attachment: Pfizer
The European Commission has granted approval for Pfizer's Zirabev, which is a biosimilar drug to Avastin used in cancer treatment. Pfizer has 16 operational sites in Europe.
Subscribe Now!(All Fields Required)
Related Articles
Articles related to this company
- Pharma Company Zoetis Signs PPA with Scout Clean Energy to Support Growing ...
- China's Rongsheng Petrochemical Ups Role in Polyester Chips
- Suffolk Construction Has Hand in $1.9 Billion Worth of Projects
- U.S. Home to Billions' Worth of 2Q ESG Project Kickoffs
- Japan Hosts $832 Million in CDMO/CMO-Related Pharma Projects
Quick Links
- Home
- About Us
- Contact Us
- For Traders
Global Market Intelligence
- GMI Database Platform
- GMI Platform Tools
- Industry Coverage
- Analytics & Insights
- Advertising
